

DISCLOSURE: The following author disclosed financial relationships: N. J. Talley: Personal fees from Aviro Health, Anantara Life Sciences, Allakos, Bayer, Planet Innovation, Takeda, Japan , twoXAR, Viscera Labs, Dr Falk Pharma, Censa, Cadila PharmIncaceuticals, Progenity Inc., Sanofi-aventis, Glutagen, ARENA Pharmaceuticals, IsoThrive, BluMaiden, Rose Pharma, Intrinsic Medicine, and Comvita Mānuka Honey; patents with Nepean Dyspepsia Index, Biomarkers of IBS, Mayo/Talley, Nestec European, Singapore Provisional, and Australian Provisional Patent Application; committees for OzSage, Australian Medical Council, Australian Telehealth Integration Programme, Medicare Benefits Schedule Review Taskforce, and National Health and Medical Research Council (NHMRC) Principal Committee Asia Pacific Association of Medical Journal Editors; editor for Gastroenterological Society of Australia Board, Sax Institute, Committees of the Presidents of Medical Colleges, *Medical Journal of Australia*, *Up to Date*, and *Precision and Future Medicine*; community groups for the International Foundation for Functional GI Disorders and ausEE; funding from NHMRC to the Centre for Research Excellence in Digestive Health and as an investigator; and miscellaneous with Avant Foundation. All other authors disclosed no financial relationships.